{
  "trial_id": "NCT03026140",
  "eligibility_criteria": "Inclusion criteria:\n\n* Signed written informed consent\n* Patients at least 18 years of age\n* Non-metastatic adenocarcinoma of the colon (and rectosigmoid considered as nonrectal and not undergoing neoadjuvant treatment)\n\n  * No signs of distant metastases on CT-scan and physical examination;\n  * dMMR cohorts 3+6: >cT3 and/or N+\n\nExclusion criteria:\n\n* No signs of distant metastases\n* No signs of obstruction or macroscopic bleeding or suspicion of perforation\n* Colonoscopy must be performed after registration to obtain study-specific biopsies. If biopsies are not possible, patients cannot be included in the study\n* WHO performance status of 0 or 1\n* No previous treatment with immune checkpoint inhibitors targeting CTLA-4, PD-1 or PD-L1\n* For patients with MSS tumors: no current use of NSAIDs or COX2-inhibitors at registration and no active peptic ulcer, gastrointestinal bleeding, unstable ischemic heart disease of thrombus etiology or significant established ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease\n* No radiotherapy prior to or planned post-surgery radiotherapy\n* No history of allergy to study drug components, severe hypersensitivity reaction to any monoclonal antibody, allergy or severe hypersensitivity to NSAIDs or COX2-I (MSS tumors)\n* No intercurrent illnesses, including but not limited to infections, unstable angina pectoris\n* No positive test for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection\n* No autoimmune disease\n* No conditions requiring systemic treatment with either corticosteroids (10 mg daily prednisone or more and equivalents) or other immunosuppressive medications within 14 days of study drug administration\n* No live vaccines in the 4 weeks prior to inclusion",
  "sanitised_criteria": "```\nInclusion criteria:\n\n- Patients at least 18 years of age\n- Non-metastatic adenocarcinoma of the colon (and rectosigmoid considered as nonrectal and not undergoing neoadjuvant treatment)\n  - No signs of distant metastases on CT-scan and physical examination\n  - dMMR cohorts 3+6: >cT3 and/or N+\n\nExclusion criteria:\n\n- No signs of distant metastases\n- No signs of obstruction or macroscopic bleeding or suspicion of perforation\n- Colonoscopy must be performed after registration to obtain study-specific biopsies\n- WHO performance status of 0 or 1\n- No previous treatment with immune checkpoint inhibitors targeting CTLA-4, PD-1 or PD-L1\n- For patients with MSS tumors: no current use of NSAIDs or COX2-inhibitors at registration\n- For patients with MSS tumors: no active peptic ulcer, gastrointestinal bleeding, unstable ischemic heart disease of thrombus etiology\n- For patients with MSS tumors: no significant established ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease\n- No radiotherapy prior to or planned post-surgery radiotherapy\n- No history of allergy to study drug components\n- No severe hypersensitivity reaction to any monoclonal antibody\n- No allergy or severe hypersensitivity to NSAIDs or COX2-I (MSS tumors)\n- No intercurrent illnesses, including but not limited to infections, unstable angina pectoris\n- No positive test for HBV surface antigen (HBsAg) or HCV ribonucleic acid (HCV antibody) indicating acute or chronic infection\n- No autoimmune disease\n- No conditions requiring systemic treatment with either corticosteroids (10 mg daily prednisone or more and equivalents) or other immunosuppressive medications within 14 days of study drug administration\n- No live vaccines in the 4 weeks prior to inclusion\n```",
  "eligibility_groups": [
    "default"
  ]
}